P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients. (12th March 2014)

Record Type:: Journal Article
Title:: P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients. (12th March 2014)
Main Title:: P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Authors:: Sylvan, S Eketorp
Lundin, J
Ipek, M
Palma, M
Karlsson, C
Hansson, L
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 2(2014)Supplement 2
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 2(2014)Supplement 2
Issue Display:: Volume 2, Issue 2 (2014)
Year:: 2014
Volume:: 2
Issue:: 2
Issue Sort Value:: 2014-0002-0002-0000
Page Start:
Page End:
Publication Date:: 2014-03-12
Subjects:: Chronic Lymphocytic Leukaemia -- Alemtuzumab -- Overall Response Rate -- Purine Analogue -- CD52 Monoclonal Antibody
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-2-S2-P18 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19728.xml